Galderma Announces the Results of Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis

TOKYO, October 31, 2018 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Galderma, Nestlé Skin Health’s Medical Solutions Business issued a press release regarding the results of phase 2b study of nemolizumab (CIM331) created by Chugai in patients with moderate-to-severe atopic dermatitis to investigate the efficacy and safety of nemolizumab. Please refer to the link below for details of the press release: Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis https://www.nestleskinhealth.com/news/galderma-announces-positive-results-phase-2b-study-nemolizumab-patients-moderate-severe-atopic [Reference] Press release issued on July 21, 2016: Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases https://www.chugai-pharm.co.jp/english/news/detail/20160721083000.html

The release as fetched from its publisher. chugai-pharm.co.jp ↗